Browse by Category
Browse by Location
Search
Tag Cloud
anthrax Strategic National Stockpile Training exercise Bioterror Biomagnetics National Research Council Homeland Security Biodefense lab Army Medical Research Institute antibiotics Emergency preparedness research Bioweapons NIAID smallpox Detection technology CDC TSA Defense Dept IAEM FEMA immunization Ebola Ricin Hendra Plague treaty West Nile Camouflage Paint Marburg antidote weapons destruction Sarin VHF viruses chemical disposal dna technology prevention Robotics Technology research grants tularemia weapons control foot and mouth disease decontamination E. coli Iraq missile defenseSubscribe to our newsletter
RSS Feed
Baxter International, Inc., investigates rapid vaccine producing U.S. facility
by Nick Rees on November 27, 2009
Baxter International, Inc., based in Deerfield, Illinois, has begun the investigation process to build a cell-based vaccine manufacturing plant in the U.S.
Baxter joins a host of other drugmakers expressing interest in the potentially lucrative U.S. vaccine market. Increased government subsidies are making the vaccine business, which has traditionally offer little profit, more attractive.
Ealier this weak, Swiss pharmaceutical giant Novartis AG began the design and construction on a $1 billion cell-based manufacturing plant in North Carolina backed by over $400 million in federal funds. That plant isn't expected to be at full-scale commercial production levels until 2013 though it could produce vaccines in an emergency as soon as 2011.
Both Novartis AG and Baxter's vaccine production facilities will utilize cell-based technology, which will allow the vaccine production timetable to be increased.
Vaccine plants have become a vital option recently as capacity issues have forced governments worldwide to re-examine their vaccine stockpiles. Shortages and rationing of vaccines are currently feared in the event of pandemic viruses.
The Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism, a bipartisan group created by Congress that advocates for money for vaccine development, has pushed for as much as $3 billion to be spent this year to enhance the United States' vaccine preparedness. That number is ten times the annual spending currently budgeted.
More News
- Soligenix announces heightened stability for RiVax
- New study shed light on how citizens will react to bio-outbreak
- Deep-UV could hold key to fighting bioattacks
- Kansas lauds proposed $40 million for biodefense facility
- Experts expect CBRN attack on U.S. within six months
- Study begins to find more effective manner of fighting smallpox
- Scott Habig joins Human Genome Sciences
- Sebelius responds to president's 2011 HHS budget
- Missile interceptor fails in mock attack
- Las Vegas expected to approve grants to fight bioterror
Read all news